Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

SHTAC begins a new five-year National Institute for Health and Care Research (NIHR) funding award

Published: 28 March 2022
SHTAC continue to appraise health technologies

SHTAC are part of the School of Healthcare Enterprise and Innovation.

The award, which begins on 1st April, will enable SHTAC to continue and expand its long-standing programme of independent health technology assessment reports (TARs) to inform National Institute for Health and Clinical Excellence (NICE) guidance on treatments for the NHS in England.

Over the next five years SHTAC’s research team (with expertise in systematic reviewers, health economics, and information science) will critically analyse and model research evidence to estimate the clinical effectiveness and cost-effectiveness of treatments for a vast range of conditions, including cancers, obesity and cardiovascular disease, amongst others. SHTAC will also assess clinical effectiveness and cost effectiveness of highly specialised treatments for rare diseases, and diagnostic tests for a range of health conditions.

Each TAR research report produced by SHTAC is scrutinised by a NICE appraisal committee of senior professionals, commissioners and lay members. They will judge, based on the robustness of the available evidence, whether the treatment provides meaningful benefit to patients, with minimal risk of harm and can be considered acceptable value for money to the NHS.

Each treatment is appraised by NICE as close as possible to its market launch, to allow patients to receive, subject to cost-effectiveness, novel, often life extending, new treatments without delay. NICE guidance on whether or not a treatment can be provided by the NHS must be implemented by NHS trusts within three months.

You can access all SHTAC’s published TAR reports to date from our Research page.

Co-principal investigator Dr Jonathan Shepherd commented:

 “This is SHTAC’s fifth consecutive five-year research award for NICE and the NIHR, at a time when demand for NICE appraisals of new treatments has never been higher. SHTAC has committed to increase its share of the work to assess the evidence to inform national decision making. It is truly gratifying when your research facilitates timely NHS access to vital new effective treatments. Ultimately this benefits health, well-being and prosperity for us all.”




Privacy Settings